Trevogrumab 1 mg — 3 mL vial

Trevogrumab, also designated REGN1033, is a fully human monoclonal antibody rather than a short peptide. Its proposed role is to neutralize myostatin, or GDF8, a protein that restrains skeletal-muscle growth. In the original preclinical publication, investigators reported selective myostatin binding and inhibition of downstream Smad2/3 signaling, without detectable binding to the related proteins GDF11 and activin A. In young and aged mice, they observed larger muscle fibers, increased muscle mass and force, and reduced muscle loss in several experimental atrophy settings. [1]

Regeneron’s June 2025 interim COURAGE announcement describes human obesity research combining semaglutide with trevogrumab, with or without the separate anti-activin-A antibody garetosmab. The company reported greater preservation of lean mass and greater fat-mass loss than with semaglutide alone; these are findings from the specified combinations, not a description of trevogrumab as a stand-alone weight-loss product. [2] Umbrella Labs markets a research vial under the trevogrumab name and emphasizes muscle preservation alongside GLP-1 drugs. Its listing identifies an antibody despite using “peptide vial” as the product category; the listing alone does not establish equivalence to clinical-trial material. [3]